Mobile Site ›

The Classic Myeloproliferative Neoplasms

Optimizing Laboratory Testing for Hematologic Disorders Series

JAK2 V617F Background

Slide 10

October 2011

As background, the JAK2 V617F plays a very important diagnostic role in the evaluation of the myeloproliferative neoplasms. If the mutation is present, it certainly confirms the presence of a myeloid disorder and strongly favors a myeloproliferative neoplasm over a myelodysplastic syndrome diagnosis. However, a positive JAK2 V617F mutation does not help distinguish between the various myeloproliferative neoplasms. As you can see in the right-hand column, the JAK2 V617F mutation is present in over 95% of cases of PV, approximately half of PMFs and ETs, and only rare cases of myelodysplastic syndrome or chronic myelomonocytic leukemia.

JAK2 V617F Background


Jump to section: